Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St set for tepid open as oil prices fall, Treasury yields rise
- Oil prices edge lower on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Jazz Pharmaceuticals (JAZZ) PT Lowered to $190 at Stifel Following 4Q
March 1, 2017 9:00 AM ESTStifel lowered its price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $190.00 (from $200.00) while maintaining a Buy rating.
Analyst Annabel Samimy commented, "JAZZ reported 4Q16 revenue of $396.6mn (Cons. $398.3mn), representing +16.4% y/y. Top-line was driven by Xyrem with sales of $291.2mn (Cons.... More
